Management Strategies for Helicobacter Pylori-Seropositive Patients with Dyspepsia

Clinical and Economic Consequences

Published In: Annals of Internal Medicine, v. 126, no. 4, Feb. 15, 1997, p. 280-290

Posted on RAND.org on January 01, 1997

by Joshua J. Ofman, Jeff A. Etchason, Steven Fullerton, Katherine L. Kahn, Andrew H. Soll

Read More

Access further information on this document at www.annals.org

This article was published outside of RAND. The full text of the article can be found at the link above.

Compares two strategies for the management of Helicobacter pylori-seropositive patients with dyspepsia. In such patients there are two strategies of treatment. One would be to treat with anti-H. pylori therapy, and the other to do initial endoscopy. This study used decision analysis to compare these two strategies and concluded in H. pylori-seropositive patients with dyspepsia, initial anti-H. pylori therapy is the most cost-effective management strategy; however, to optimize management decisions, randomized trials are still necessary to evaluate outcomes in patient preferences. In the meantime, the use of anti-H. pylori therapy as opposed to endoscopy in such patients is suggested by the decision analysis done in this paper. Since this condition affects large numbers of people, this paper can have positive effects on both the cost of care and the quality of care for patients with GI distress who also are affected with H. pylori.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.